Clinical Trial Update: Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ARRY-614 in combination with nivolumab or nivolumab plus ipilimumab (Phase 1/2) currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• ARRY-614
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Dan Zandberg | Conditions: Renal Cell Carcinoma, Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING